• Prescribing information at bottom of page
Image of hands holding the World with a green background

Choose Accuhaler, stay with Ventolin, reduce carbon

Ventolin Accuhaler list price reduced by 45% from 1st August 2022 making it more affordable for patients who need a SABA

To support low carbon prescribing and enable you to stay with Ventolin, the price of the Accuhaler has been reduced from 1st August 2022.

  List price Actuations per pack Cost per actuation
Ventolin 200mcg Accuhaler  £1.99 60 £0.03
 
Ventolin 100mcg Evohaler £1.50 200 £0.01

Patients should be prescribed the strength that is clinically appropriate to meet their needs. A patient should be reviewed before making any change in treatment 

How does the price of Ventolin Accuhaler now compare with the Easyhaler Salbutamol?

Pack Strength List price Actuations per pack Cost per actuation
Ventolin Accuhaler  200mcg  £1.99 60 £0.03
Easyhaler Salbutamol  £6.63  200 £0.03
 
Easyhaler Salbutamol 100mcg £3.31  200 £0.02

Patients should be prescribed the strength that is clinically appropriate to meet their needs. A patient should be reviewed before making any change in treatment

Consult product SmPCs for specific indications and dosing regimens

Ventolin Accuhaler Indication1

Ventolin Accuhaler is indicated in adults, adolescents and children aged 4 to 11 years. Ventolin Accuhaler can be used in the management of asthma, bronchospasm and/or reversible airways obstruction.

Dosing2

Adults, adolescents aged 12 years and over and children 4 to 11 years of age:

  • to relieve asthma - one inhalation (200 micrograms)
  • to prevent asthma - one inhalation (200 micrograms) 10 to 15 minutes before exercise or exposure to a “trigger”
  • the maximum dose is one inhalation (200 micrograms) four times a day
Picture of a Ventolin (salbutamol) Accuhaler device

Be proactive, control asthma: resources to help you to support patients

Choose Accuhaler, reduce carbon

References

  1. Ventolin SmPC
  2. Ventolin Patient Information Leaflet (PIL)
  3. Nathan RA et al. J Allergy Clin Immunol 2004;113:59-65
  4. IQVIA prescribed data volume MAT April 2022

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
Third party trade marks are the property of their respective owners

July 2022 | PM-GB-CEP-WCNT-220002 (V1.0)